MicroRNA-19a functions as an oncogenic microRNA in non-small cell lung cancer by targeting the suppressor of cytokine signaling 1 and mediating STAT3 activation

Wang,Xuguang; Chen,Zhe

doi:10.3892/ijmm.2015.2071

MicroRNA-19a functions as an oncogenic microRNA in non-small cell lung cancer by targeting the suppressor of cytokine signaling 1 and mediating STAT3 activation

Authors:
- Xuguang Wang
- Zhe Chen
View Affiliations

Affiliations: Department of Thoracic Surgery, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450014, P.R. China, Department of Radiology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450014, P.R. China
Published online on: January 19, 2015 https://doi.org/10.3892/ijmm.2015.2071
Pages: 839-846

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA‑19a (miR‑19a) has been found to be overexpressed in lung cancers. However, the underlying molecular mechanisms of miR‑19a in tumorigenesis and the development of lung cancer remain poorly understood. In the present study, we aimed to delineate the role and mechanisms of action of miR‑19a in non‑small cell lung cancer (NSCLC). miR‑19a was found to be overexpressed in both NSCLC tumor tissues and cell lines, as shown by RT-PCR. The enforced expression of miR‑19a by transfection with miR-19a mimics significantly enhanced cell growth and viability, cell invasion and the migration of NSCLC cells, as shown by cell invasion and migration assays, and promoted the growth of xenograft tumors in a mouse xenograft tumor model. Conversely, the inhibition of miR‑19a by transfection of the cells with miR‑19a inhibitor displayed the opposite effects. More importantly, we found that miR‑19a directly interacted with the 3'‑untranslated region (3'‑UTR) of the suppressor of cytokine signaling 1 (SOCS1) by dual‑luciferase reporter assay. miR‑19a was found to be capable of regulating the expression of SOCS1 in NSCLC cells. Thus, by modulating SOCS1 expression, miR‑19a regulated the expression of the signal transducer and activator of transcription 3 (STAT3). Taken together, our data provide a possible underlying mechanism of action of miR‑19a in the development of NSCLC and suggest that miR‑19a may be a novel and promising target for therapeutic intervention in NSCLC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Claassens L, van Meerbeeck J, Coens C, et al: Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol. 29:2104–2120. 2011. View Article : Google Scholar : PubMed/NCBI
3	Hu Z, Chen X, Zhao Y, et al: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 28:1721–1726. 2010. View Article : Google Scholar : PubMed/NCBI
4	Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
5	Blumenschein GR Jr and Herbst RS: Integration of targeted therapies in gemcitabine chemotherapy regimens. Clin Lung Cancer. 4:217–223. 2003. View Article : Google Scholar : PubMed/NCBI
6	Cabebe E and Wakelee H: Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol. 8:15–27. 2007. View Article : Google Scholar : PubMed/NCBI
7	Ranganathan K and Sivasankar V: MicroRNAs - Biology and clinical applications. J Oral Maxillofac Pathol. 18:229–234. 2014. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Winter J, Jung S, Keller S, Gregory RI and Diederichs S: Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
10	Rottiers V, Najafi-Shoushtari SH, Kristo F, et al: MicroRNAs in metabolism and metabolic diseases. Cold Spring Harb Symp Quant Biol. 76:225–233. 2011. View Article : Google Scholar : PubMed/NCBI
11	Aigner A: MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs. J Mol Med (Berl). 89:445–457. 2011. View Article : Google Scholar
12	Zimmerman AL and Wu S: MicroRNAs, cancer and cancer stem cells. Cancer Lett. 300:10–19. 2011. View Article : Google Scholar
13	Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
14	Wang P, Chen L, Zhang J, et al: Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene. 33:514–524. 2014. View Article : Google Scholar
15	Oh JS, Kim JJ, Byun JY and Kim IA: Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int J Radiat Oncol Biol Phys. 76:5–8. 2010. View Article : Google Scholar
16	Wang P, Zhuang L, Zhang J, et al: The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol Oncol. 7:334–345. 2013. View Article : Google Scholar
17	Petrocca F, Visone R, Onelli MR, et al: E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 13:272–286. 2008. View Article : Google Scholar : PubMed/NCBI
18	Wu Q, Yang Z, An Y, et al: MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1. Cell Death Dis. 5:e11442014. View Article : Google Scholar : PubMed/NCBI
19	Xu XM, Wang XB, Chen MM, et al: MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. Cancer Lett. 322:148–158. 2012. View Article : Google Scholar : PubMed/NCBI
20	Yu G, Li H, Wang X, et al: MicroRNA-19a targets tissue factor to inhibit colon cancer cells migration and invasion. Mol Cell Biochem. 380:239–247. 2013. View Article : Google Scholar : PubMed/NCBI
21	Lin Q, Chen T, Lin Q, Lin G, et al: Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer. J Surg Oncol. 107:767–771. 2013. View Article : Google Scholar : PubMed/NCBI
22	Yu H and Jove R: The STATs of cancer - new molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004. View Article : Google Scholar : PubMed/NCBI
23	Tian M, Wan Y, Tang J, et al: Depletion of tissue factor suppresses hepatic metastasis and tumor growth in colorectal cancer via the downregulation of MMPs and the induction of autophagy and apoptosis. Cancer Biol Ther. 12:896–907. 2011. View Article : Google Scholar : PubMed/NCBI
24	Zhang J, Li H, Yu JP, Wang SE and Ren XB: Role of SOCS1 in tumor progression and therapeutic application. Int J Cancer. 130:1971–1980. 2012. View Article : Google Scholar
25	Huang C, Li H, Wu W, Jiang T and Qiu Z: Regulation of miR-155 affects pancreatic cancer cell invasiveness and migration by modulating the STAT3 signaling pathway through SOCS1. Oncol Rep. 30:1223–1230. 2013.PubMed/NCBI
26	Cittadini A, Monti MG, Iaccarino G, et al: SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway. Cardiovasc Res. 96:381–390. 2012. View Article : Google Scholar : PubMed/NCBI
27	Liu L, Li W, Wei X, et al: Potent antitumor activity of oncolytic adenovirus-mediated SOCS1 for hepatocellular carcinoma. Gene Ther. 20:84–92. 2013. View Article : Google Scholar
28	Xu XL, Jiang YH, Feng JG, et al: MicroRNA-17, microRNA-18a, and microRNA-19a are prognostic indicators in esophageal squamous cell carcinoma. Ann Thorac Surg. 97:1037–1045. 2014. View Article : Google Scholar
29	Sochor M, Basova P, Pesta M, et al: Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer. 14:4482014. View Article : Google Scholar : PubMed/NCBI
30	Navarro A, Marrades RM, Vinolas N, et al: MicroRNAs expressed during lung cancer development are expressed in human pseudoglandular lung embryogenesis. Oncology. 76:162–169. 2009. View Article : Google Scholar : PubMed/NCBI
31	Chen Q, Xia HW, Ge XJ, et al: Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac J Cancer Prev. 14:7421–7426. 2013. View Article : Google Scholar
32	Murphy BL, Obad S, Bihannic L, et al: Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. Cancer Res. 73:7068–7078. 2013. View Article : Google Scholar : PubMed/NCBI
33	Li X, Xie W, Xie C, et al: Curcumin modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7 breast cancer cell proliferation. Phytother Res. 28:1553–1560. 2014. View Article : Google Scholar : PubMed/NCBI
34	Wu TY, Zhang TH, Qu LM, et al: MiR-19a is correlated with prognosis and apoptosis of laryngeal squamous cell carcinoma by regulating TIMP-2 expression. Int J Clin Exp Pathol. 7:56–63. 2013.
35	Wang F, Li T, Zhang B, et al: MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun. 434:688–694. 2013. View Article : Google Scholar : PubMed/NCBI
36	Krebs DL and Hilton DJ: SOCS proteins: negative regulators of cytokine signaling. Stem Cells. 19:378–387. 2001. View Article : Google Scholar : PubMed/NCBI
37	Yasukawa H, Sasaki A and Yoshimura A: Negative regulation of cytokine signaling pathways. Annu Rev Immunol. 18:143–164. 2000. View Article : Google Scholar : PubMed/NCBI
38	He Y, Zhang W, Zhang R, Zhang H and Min W: SOCS1 inhibits tumor necrosis factor-induced activation of ASK1-JNK inflammatory signaling by mediating ASK1 degradation. J Biol Chem. 281:5559–5566. 2006. View Article : Google Scholar : PubMed/NCBI
39	Hanada T, Yoshida H, Kato S, et al: Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity. 19:437–450. 2003. View Article : Google Scholar : PubMed/NCBI
40	Chinen T, Kobayashi T, Ogata H, et al: Suppressor of cytokine signaling-1 regulates inflammatory bowel disease in which both IFNgamma and IL-4 are involved. Gastroenterology. 130:373–388. 2006. View Article : Google Scholar : PubMed/NCBI
41	Sasi W, Sharma AK and Mokbel K: The role of suppressors of cytokine signalling in human neoplasms. Mol Biol Int. 2014:6307972014. View Article : Google Scholar : PubMed/NCBI
42	Chu PY, Yeh CM, Hsu NC, et al: Epigenetic alteration of the SOCS1 gene in hepatocellular carcinoma. Swiss Med Wkly. 140:w130652010.PubMed/NCBI
43	Neuwirt H, Puhr M, Santer FR, et al: Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. Am J Pathol. 174:1921–1930. 2009. View Article : Google Scholar : PubMed/NCBI
44	Komazaki T, Nagai H, Emi M, et al: Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers. Jpn J Clin Oncol. 34:191–194. 2004. View Article : Google Scholar : PubMed/NCBI
45	Lesinski GB, Zimmerer JM, Kreiner M, et al: Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells. BMC Cancer. 10:1422010. View Article : Google Scholar : PubMed/NCBI
46	Zitzmann K, Brand S, De Toni EN, et al: SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res. 67:5025–5032. 2007. View Article : Google Scholar : PubMed/NCBI
47	Zhao M, Gao FH, Wang JY, et al: JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. Lung Cancer. 73:366–374. 2011. View Article : Google Scholar : PubMed/NCBI
48	Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 9:798–809. 2009. View Article : Google Scholar : PubMed/NCBI
49	Souma Y, Nishida T, Serada S, et al: Antiproliferative effect of SOCS-1 through the suppression of STAT3 and p38 MAPK activation in gastric cancer cells. Int J Cancer. 131:1287–1296. 2012. View Article : Google Scholar
50	Xu Y, Xu X, Gao X, Chen H and Geng L: Shikonin suppresses IL-17-induced VEGF expression via blockage of JAK2/STAT3 pathway. Int Immunopharmacol. 19:327–333. 2014. View Article : Google Scholar : PubMed/NCBI
51	Shimada K, Serada S, Fujimoto M, et al: Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signaling-1 in non-small-cell lung cancer cells. Cancer Sci. 104:1483–1491. 2013. View Article : Google Scholar : PubMed/NCBI